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Most individuals with Down syndrome show early onset of
Alzheimer disease (AD), resulting from the extra copy of
chromosome 21. Located on this chromosome is a gene that
encodes the dual specificity tyrosine phosphorylation-regu-
lated kinase 1A (DYRK1A). One of the pathological hallmarks
in AD is the presence of neurofibrillary tangles (NFTs), which
are insoluble deposits that consist of abnormally hyperphos-
phorylated Tau. Previously it was reported that Tau at the
Thr-212 residue was phosphorylated by Dyrk1A in vitro. To
determine the physiological significance of this phosphoryl-
ation, an analysis was made of the amount of phospho-Thr-
212-Tau (pT212) in the brains of transgenic mice that over-
express the human DYRK1A protein (DYRK1A TGmice) that
we recently generated. A significant increase in the amount of
pT212 was found in the brains of DYRK1A transgenic mice
when compared with age-matched littermate controls. We
further examined whether Dyrk1A phosphorylates other Tau
residues that are implicated in NFTs. We found that Dyrk1A
also phosphorylates Tau at Ser-202 and Ser-404 in vitro.
Phosphorylation by Dyrk1A strongly inhibited the ability of
Tau to promote microtubule assembly. Following this, using
mammalian cells and DYRK1A TGmouse brains, it was dem-
onstrated that the amounts of phospho-Ser-202-Tau and
phospho-Ser-404-Tau are enhanced when DYRK1A amounts
are high. These results provide the first in vivo evidence for a
physiological role of DYRK1A in the hyperphosphorylation
of Tau and suggest that the extra copy of the DYRK1A gene
contributes to the early onset of AD.
Down syndrome (DS)3 is the most common genetic disorder
with a frequency of 1 in 800 live births, and it is caused by the
presence of an extra copy of whole or part of human chromo-
some 21 (1, 2). DS patients suffer various symptoms, including
congenital heart defects, immune and endocrine system
defects, mental retardation, and early onset of Alzheimer dis-
ease (AD) (3). Both DS and AD patients have pathological hall-
marks, amyloid plaques and neurofibrillary tangles (NFTs) that
are insoluble deposits made of proteins called -amyloid (A)
and hyperphosphorylated Tau, respectively (4–6). Although
an early onset AD in DS patients is not clearly understood, one
potential mechanism is the presence of three chromosomal
copies of -amyloid precursor protein (APP) gene. However,
the APP overexpression alone in mice does not show the endo-
some abnormalities observed in AD-like pathology (7), imply-
ing the necessity of additional genes on the chromosome 21 for
a full spectrum of AD pathologies.
NFTs found in AD are composed of paired helical filaments
(PHFs), which are mainly composed of hyperphosphorylated
Tau protein (8). To date, more than 30 phosphorylation sites and
7–10 mol of phosphates per mol of Tau have been observed in
PHF-Tau (9, 10). Although Tau protein is phosphorylated in vitro
by numerous kinases, it is unclear how many kinases actually
phosphorylate Tau in vivo. Currently, only glycogen synthase
kinase 3 (GSK3), cyclin-dependent kinase 5, cAMP-depend-
ent protein kinase A, and microtubule affinity-regulating
kinase are known to modulate Tau phosphorylation in vivo at
some level, either directly or indirectly (11).
TheDYRK1A (dual specificity tyrosine (Y)-phosphorylation-
regulated kinase 1A) gene is isolated from human chromosome
21 and encodes a protein kinase (12–15). DYRK1A is ubiqui-
tously expressed with strong expression in brain and heart (13,
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overexpressed (19). Dyrk1A has dual substrate specificities as
follows: autophosphorylation on the tyrosine 321 residue for
self-activation and phosphorylation of target proteins on ser-
ine/threonine residues with a preferred phosphorylation con-
sensus motif of RPX(S/T)P (12, 20, 21). Dyrk1A potentially
phosphorylates or interacts with several proteins, including
transcription factors (NFATc, STAT3, Forkhead, CREB, and
Gli1) and eukaryotic initiation factor 2B, Dynamin 1, cyclin L2,
Hip-1, and -synuclein, implying the multiple biological func-
tions of DYRK1A (22). Dyrk1A knock-out mice show a general
delay in fetal development and are embryonic lethal, indicating
the vital andnonredundant biological functions ofDyrk1A (23).
We recently generated transgenic mice that overexpress
human DYRK1A (DYRK1A TG mice) by introducing a bacte-
rial artificial chromosome that only carries the human
DYRK1A genomic DNA, including the endogenous promoter
(24). These DYRK1A TGmice show learning and memory def-
icits similar to what is seen in DS patients, a finding that is
comparable with previous studies on themouse Dyrk1A cDNA
transgenic mice or the human genomic transgenic mice carry-
ing a few chromosome 21 genes, including DYRK1A on a yeast
artificial chromosome (24–26).
Previously, it was reported that Dyrk1A phosphorylates Tau
at Thr-212 in vitro, a residue that is phosphorylated in fetal Tau
and hyperphosphorylated in filamentous Tau from AD brains
(27). In this study, we investigated the physiological signifi-
cance of this phosphorylation event using transgenic mice that
overexpress humanDYRK1A (DYRK1ATGmice). It was found
that that Tau phosphorylation at Thr-212 is significantly
increased in DYRK1A TGmice. Furthermore, Tau protein was
also phosphorylated at Ser-202 and Ser-404 residues byDyrk1A
in vitro, and the levels of the phosphorylation at those residues
were increased in DYRK1A TG mice. These results indicate
that the overexpression of DYRK1A in DS brains may contrib-
ute to early onset of AD pathology through the hyperphospho-
rylation of Tau.
EXPERIMENTAL PROCEDURES
Proteins and Antibodies—The full-length mouse Dyrk1A
cDNAs (wild-type and Y321F kinase-inactive mutant) were
cloned into pET-25b (Novagen), followed by isopropyl 1-thio-
-D-galactopyranoside induction inEscherichia coliBL21(DE3)
codon plus RIL (Stratagene). Using its endogenous 13-histidine
repeat, the Dyrk1A protein was purified with nickel-nitrilotriace-
tic acid resin as described by the manufacturer (Qiagen). Human
recombinant Tau, nonglycosylated and nonphosphorylated form
of 441-amino acid Tau splice variant, was obtained from Calbio-
chem. Bovine tubulin was purchased from Cytoskeleton, and
JNK2was fromUpstate.Antibodies forTau (Tau-5) andphospho-
Tau (pS202, pT212, pS404) were obtained from BIOSOURCE.
Phosphopeptides and non-phosphopeptides were purchased to
perform the peptide competition assay for all three phospho-Tau
antibodies (BIOSOURCE). The anti-Dyrk1A antibody was cus-
tom-made as described previously (24).
Immunohistochemistry—Micewere anesthetizedwith isoflu-
rane, and perfused transcardially with phosphate-buffered
saline (PBS, pH 7.4) followed by fixative (4% paraformaldehyde
in PBS, pH 7.4). The brains were fixed at 4 °C overnight and
were cryoprotected. Sagittal sections ofmouse brains were pre-
pared as described previously (24) and incubated first with
phospho-Tau antibodies (pS202, pT212, and pS404; 1:100 dilu-
tion), then with biotinylated anti-rabbit IgG (1:200 dilution),
and finally with avidin biotinylated horseradish peroxidase
(Vector Laboratories). After visualization with an SG reagent
set (Vector Laboratories), signals were examined with a Zeiss
Axioplan microscope using conventional optics.
Preparation of Mouse Brain Lysates and Immunoblotting—
DYRK1A TG mice that overexpressed the human DYRK1A
gene, which was transcribed from the genomic DYRK1A DNA
carried on a bacterial artificial chromosome, were produced
andmaintained as described previously (24). Experiments were
performed in accordance with guidelines set forth by the Inje
University Council Directive for the proper care and use of
laboratory animals. Mouse brain lysates were prepared by
homogenization in a tissue grinder (Fisher) in RIPA buffer (150
mMNaCl, 1%Nonidet P-40, 0.1% SDS, 50mMTris, pH 8.0, 0.5%
deoxycholic acid) containing a protease inhibitor mixture (Cal-
biochem), 20 M sodium orthovanadate, and 1 mM phenyl-
methylsulfonyl fluoride. The protein concentration was deter-
mined using the BCAmethod (Sigma). Proteins were separated
by SDS-PAGE and analyzed by immunoblot with phospho-Tau
and Tau antibodies. Densitometric quantification of Western
blotting signal bands was carried out with a Science Lab 2001
Image Gauge (version 4.0, Fuji Photo Film Co., Ltd.).
In Vitro Tau Phosphorylation—Human recombinant Tau
protein (1.1 g) was incubated for 90 min at 30 °C with the
purified Dyrk1A (300 ng) in kinase buffer (20 mM MOPS, pH
7.0, 10 mM MgCl2, 1 mM dithiothreitol, 20 M sodium
orthovanadate, and 100 M ATP; 30-l reaction volume). The
reaction mixtures were separated on SDS-PAGE and analyzed
by immunoblot with Tau and phospho-Tau antibodies.
Microtubule Assembly—Tau protein (9.2 M) was phospho-
rylated by either no kinase, JNK2 (0.83 M), or Dyrk1A (0.90
M) for 2 h as described above. Phosphorylated Tau proteins
were subjected tomicrotubule assembly assay as described pre-
viously (28). Briefly, nonphosphorylated or phosphorylated
Tau (final concentration, 1.3 M) was mixed with tubulin (20
M) in polymerization buffer (80 mMNa-PIPES, pH 6.9, 10 mM
MgCl2, 1 mM EGTA and 1 mM GTP) at 37 °C. Microtubule
assembly was initiated by addition of glycerol (final concentra-
tion, 5%) and was monitored by measuring the absorbance at
340 nm over 20 min.
Plasmids, siRNAs, and HEK293T Cell Transfection—A full-
length wild-type Dyrk1A cDNA from a mouse brain and a full-
length humanTau cDNAwere cloned into pcDNA3.1 (Invitro-
gen). The Y321F kinase-inactive mutant Dyrk1A cDNA was
generated by DpnI-mediated site-directed mutagenesis. For
siRNA experiment, the mouse Dyrk1A-specific siRNA (5-
GGUAUGAAAUCGACUCCUU) with the TT overhang was
designed and synthesized by Samchully Pharm. Co. (South
Korea). For siRNA delivery, Dyrk1A-specific duplex siRNA (60
pmol for 6-well plate) was co-transfected into human embry-
onic kidney (HEK293T) cells (8 105 cells/well) with Dyrk1A
and Tau plasmids using Lipofectamine 2000 (Invitrogen). Flu-
orescein isothiocyanate-conjugated GFP-specific siRNA (5-
GUUCAGCGUGUCCGGCGAGTT) was used as a nonsilenc-
Tau Hyperphosphorylation by DYRK1A
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ing control. After 24 h of siRNA treatment, cell lysates were
prepared for immunoblot analyses.
Immunocytochemistry—COS-7 cells on PDL-coated cover-
slip (6-well) were transfected with Dyrk1A and Tau plasmids.
After 24 h, cells were fixed with 4% (w/v) paraformaldehyde in
PBS, pH 7.4, permeabilized with 0.1% Triton X-100 in PBS, and
blocked with PBS containing 1% normal goat serum for 2 h.
Cells were incubated with the primary antibodies (Dyrk1A,
1:200; Tau, 1:500) at room temperature for 2 h, and then with
Alexa Fluor 488 goat anti-rabbit or
Cy3 goat anti-mouse-coupled sec-
ondary antibodies (1:200) for 1 h.
Technical support by examining the
images using a confocal microscope
(Carl Zeiss LSM 510) was provided
by the Korea Basic Science Institute.
Co-immunoprecipitation—Brain
lysate (1 mg) from the DYRK1A TG
mice was incubated with control
IgG (R & D Systems), Tau (BIO-
SOURCE), or Dyrk1A antibody for
overnight at 4 °C in RIPA buffer
with protease inhibitors and 1 mM
phenylmethylsulfonyl fluoride. The
next day after a 1-h incubation with
protein A beads (Pierce), the beads
were gently washed with 1% Triton
X-100 in RIPA buffer, and then the
bound proteins were subjected to
immunoblot analysis for the indi-
cated antibodies.
RESULTS
Increased Phospho-Thr-212-Tau
in DYRK1A TG Mice—To investi-
gate the link between DYRK1A and
Tau phosphorylation at theThr-212
residue in vivo, transgenic mice
that overexpress human DYRK1A
(DYRK1A TG mice) were analyzed.
These DYRK1A TGmice contained
two copies of the mouse Dyrk1A
gene and one copy of the human DYRK1A genomic DNA, and
the human DYRK1A protein expression was tightly controlled
by the endogenous promoter. The overexpression of DYRK1A in
these mice resulted in approximately a 70% increase in kinase
activity.4 Immunohistochemical analyses revealed that phospho-
Thr-212-Tau (pT212) expression was markedly increased in the
hippocampus and frontal cortex of DYRK1A TG mice com-
pared with control littermates (Fig. 1,A and B). The increase in
pT212 was observed in the pyramidal cell layer of the hip-
pocampus and the polymorphic layer of the dentate gyrus
where DYRK1A overexpression was observed previously (24).
The results were corroborated by Western analysis of brain
lysates prepared from the hippocampus of DYRK1A TG mice
and control littermates (Fig. 1C). After normalizationwith Tau,
the amounts of pT212 in the DYRK1ATGmice were increased
by 49  18% (n  8, p  0.05), relative to control littermates.
The fact that increased phosphorylation of Tau at Thr-212 was
evident in both immunohistochemical and immunoblot exper-
iments suggests that overexpression of DYRK1A is functionally
linked to Tau phosphorylation in vivo.
4 Ryoo, S.-R., Cho, H.-J., Lee, H.-W., Jeong,H. K., Radnaabazar, C., Kim, Y.-S., Kim,
M.-J., Son, M.-Y., Seo, H., Chung, S.-H., and Song, W.-J., J. Neurochem., in
press.
FIGURE 1. Increased phospho-Thr-212-Tau in the DYRK1A TG mouse brain. Immunohistochemistry of
sagittal sections of hippocampus (A) and frontal cortex (B) fromDYRK1A TGmice (8-week-old, lower panel) and
control littermates (upper panel) performed with a phospho-Thr-212-Tau (pT212)-specific antibody. The fig-
ures shownare representativeof results obtainedwith3pairs ofDYRK1ATGandcontrol littermatemice.Panels
a and d, CA1; panels b and e, CA3; panels c and f, polymorphic layer of the dentate gyrus. A,50; panels a–f,
400; B,400. C, immunoblots of hippocampal lysates of 4–8-week old DYRK1A TG mice and control litter-
mates carriedoutwithDyrk1A, pT212, andTauantibodies (left panel). Densitometric analysis (right panel) of the
immunoblots was normalized with respect to the Tau signal. The amount of pT212 in DYRK1A TG mice is
plotted as the percent of that inwild-type littermate controls. Data are shownasmeans S.E. *, p 0.05 versus
littermate control by Student’s t test.
FIGURE 2. In vitro phosphorylation of Tau at Ser-202 and Ser-404 by
Dyrk1A. A, human recombinant Tau protein was phosphorylated in vitro in
the presence or absence of purified Dyrk1A. The reactionmixtures were sub-
jected to SDS-PAGE, followed by immunoblot analyses with phospho-Ser-
202-Tau (pS202), phospho-Ser-404-Tau (pS404), and Tau antibodies. B, Tau
wasphosphorylatedbywild-type (WT) andY321F kinase-inactivemutant (YF)
Dyrk1A protein in vitro and was then subjected to immunoblot analysis for
pS202, Tau, and Dyrk1A.
Tau Hyperphosphorylation by DYRK1A
34852 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 48•NOVEMBER 30, 2007
 at Y
O
N
SEI U
N
IV
ERSITY
 on February 5, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
In Vitro Phosphorylation of Tau at Ser-202 and Ser-404 by
Dyrk1A—Previously it was reported that Dyrk1A preferen-
tially phosphorylates substrate proteins at serine and/or
threonine residue(s) when proline is present at the 1 posi-
tion, (S/T)P (20). An examination of the amino acid
sequence of Tau reveals the presence of multiple serine/
threonine residues followed by proline. To further explore
the role of Dyrk1A in Tau hyperphosphorylation, we exam-
ined whether this kinase phosphorylates Tau in vitro at other
residues that are implicated in NFT formations in AD, such
as Ser-202 and Ser-404 residues (29). The full-length mouse
Dyrk1A proteins (wild-type (WT) and Y321F kinase-inactive
mutant (YF)) were expressed in E. coli and were purified as
90 kDa.4 The recombinant full-length human Tau was
incubated in the presence or absence of Dyrk1A, and the
reaction mixture was then subjected to immunoblotting
analysis. Phosphorylation of Ser-202 and Ser-404 was
detected with phospho-Ser-202-Tau (pS202)- and phospho-
Ser-404-Tau (pS404)-specific antibodies, respectively. Only
in the presence of both Tau and Dyrk1A were the pS202- and
pS404-specific antibodies able to detect a protein band that
corresponded to Tau on the immunoblotted membrane (Fig.
2A). This result indicates that Dyrk1A can phosphorylate the Ser-
202 and Ser-404 residues of Tau directly in vitro. The phosphoryl-
ation of Tau by Dyrk1A did not result from any contaminating
E. coli kinase activity during Dyrk1A purification, as the Tau
proteinwas phosphorylated only by theWTDyrk1A and not by
theY321Fmutant (Fig. 2B). TheY321FmutantDyrk1A showed
slightly faster mobility on the SDS-PAGE, because of mutation
of the Tyr-321 residue, the autophosphorylation site required
for kinase activation (Fig. 2B and
Fig. 4A). When the WT and Y321F
proteins were treated with  phos-
phatase for dephosphorylation, they
showed the same mobility (data not
shown).
Inhibition of Microtubule Assem-
bly by Dyrk1A-mediated Tau Phos-
phorylation—It is known that
hyperphosphorylated Tau inhibits
microtubule assembly, whereas
normal Tau stimulates assembly
and stabilizes the microtubule. We
examined the extent to which Tau
phosphorylation by Dyrk1A affects
the ability of Tau in promoting
microtubule assembly. Phosphoryl-
ation of Tau by Dyrk1A strongly
inhibited microtubule assembly
(Fig. 3). After incubation for 20min,
assembly of the samples incubated
with Tau phosphorylated by
Dyrk1A was inhibited by 80  7%
(n  4, p  0.01) when compared
with that of control (no kinase). The
extent of Dyrk1A-mediated inhibi-
tion was comparable with that of
JNK2, a known Tau kinase that
phosphorylates several Tau residues
(28). The strong inhibition of the
microtubule assembly in the pres-
ence of Dyrk1A supports that
Dyrk1A potentially phosphorylates
multiple residues in Tau.
FIGURE3. Inhibitionofmicrotubule assemblybyDyrk1A-mediatedphos-
phorylated Tau. Following the incubation of Tau with no kinase, JNK2 (0.83
M) or Dyrk1A (0.90 M) for 16 h at 30 °C, the reaction mixture was added to
tubulin. Tubulin polymerizationwas initiated by addition of glycerol andwas
monitoredbymeasuring turbidity at 340nm for 20min. Therewas no change
in turbidity in the absence of Tau (No Tau).
FIGURE 4. Tau phosphorylation by Dyrk1A in mammalian cells. A, HEK293T cells were transfected with
indicated plasmid(s) or a control pcDNA3.1. After 24 h, cell lysates were subjected to SDS-PAGE, followed by
immunoblot analyses for the indicated phospho-Tau, Tau, and Dyrk1A. B, HEK293T cells were co-transfected
with human Tau,mouse Dyrk1A, andDyrk1A-specific siRNAs. The level of Dyrk1A, phospho-Tau, and Tauwere
examined by immunoblot analyses. Fluorescein isothiocyanate-conjugated GFP-specific siRNA was used as a
nonsilencing siRNAcontrol (Con).C,peptide competition assay for phospho-Tauantibodies.Mousehippocam-
pal lysateswere analyzedbyWesternblottingwith indicatedphospho-specific Tau antibodies preincubated in
the absence (N) or presence of non-phosphopeptides (NP), phosphopeptides (P), or unrelated phosphopep-
tides (UP). The pS404 phosphopeptide was used as an unrelated phosphopeptide control for the pS202 anti-
body competition assay andvice versa. ThepS202phosphopeptidewasusedas anunrelatedphosphopeptide
control for the pT212 antibody.
Tau Hyperphosphorylation by DYRK1A
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Tau Phosphorylation by the Dyrk1A in Mammalian Cells—
To determine whether Dyrk1A phosphorylates full-length Tau
on Ser-202, Ser-404, and Thr-212 in vivo, a Western analysis
was performed with lysates of human embryonic kidney
(HEK293T) cells that had been transiently transfected with a
full-length Tau expression plasmid, either in the presence or
absence of a plasmid encoding mouse Dyrk1A (WT or Y321F).
Although the amounts of Tau were similar, the amounts of
pS202, pT212, and pS404 were strongly increased in cells
expressing Dyrk1AWT, but not Dyrk1A Y321F (Fig. 4A), indi-
cating that full-length Tau is phosphorylated by Dyrk1A in
cells. The Ser-202, Thr-212, and Ser-404 of Tau were weakly
phosphorylated in the absence of exogenous mouse Dyrk1A,
potentially on account of the presence of endogenous Dyrk1A
and other Tau-phosphorylating kinases, including JNK (28).
Furthermore, Y321Fmutant, a dominant negative kinase-inac-
tivemutant ofDyrk1A,may inhibit kinase activity ofDyrk1Aby
competing with endogenous Dyrk1A in HEK293T cells, result-
ing in further inhibition of Dyrk1A-mediated Tau phosphoryl-
ation, compared with that of Tau-transfected control (Fig. 4A).
To confirm the above finding,
HEK293T cells were co-transfected
with Dyrk1A siRNA along with
plasmids encoding the full-length
mouse Dyrk1A and human Tau. A
nonsilencing fluorescein isothio-
cyanate-conjugated GFP-specific
siRNA was used as a negative con-
trol. After 24 h of treatment,
Dyrk1A siRNA strongly inhibited
expression of Dyrk1A. Correspond-
ingly, the levels of pS202, pT212,
and pS404 were also reduced,
whereas Dyrk1A siRNA did not
affect Tau expression (Fig. 4B). This
result supports that Dyrk1A phos-
phorylates Tau on Ser-202,
Thr-212, and Ser-404 in vivo.
Specificity of each phospho-spe-
cific antibody was demonstrated by
the peptide competition assay. Fig.
4C showed that the specific band
signal in an immunoblot of mouse
brain lysate was blocked only when
the membrane was preincubated
with the corresponding phos-
phopeptide, but not with the non-
phosphopeptide or the unrelated
phosphopeptide.
Increase in the Amounts of Phos-
pho-Ser-202 and Phospho-Ser-404
in the Hippocampus and Frontal
Cortex of DYRK1A TG Mice—To
determine the physiological sig-
nificance of Tau phosphorylation
at the Ser-202 and Ser-404 resi-
dues, DYRK1A TGmice were ana-
lyzed with immunohistochemistry
and immunoblotting. Immunohistochemical analyses re-
vealed that pS202 and pS404 were increased in the hippocam-
pus and frontal cortex of DYRK1A TGmice relative to control
littermates (Fig. 5). Strong immunohistochemical signals were
observed in the neuronal cell bodies of the hippocampus or
apical dendrites of the frontal cortex in DYRK1A TGmice rel-
ative to those of control mice. Increases in pS202, pT212, and
pS404 were also observed in scattered neurons in the hip-
pocampus and axonal tract in the corpus callosum of DYRK1A
TG mice (Fig. 1A and Fig. 5).
The results were corroborated by Western analysis of brain
lysates prepared from the hippocampus or frontal cortex of
DYRK1A TG mice and control littermates. Immunoblot anal-
yses showed that after normalization with Tau, the amounts of
pS202 and pS404 in the hippocampal lysates of DYRK1A TG
mice were increased by 26 9% (n 11, p 0.01) and 29 7%
(n 9, p 0.05) relative to that of control littermates, respec-
tively (Fig. 6A). In addition, after normalization with Tau, the
amounts of pS202 and pS404 in the frontal cortex of DYRK1A
TGmice were also increased by 32 4% (n 3, p 0.05) and
FIGURE 5. Immunohistochemical analysis of pS202 and pS404 levels in the DYRK1A TG mice. A and B,
immunohistochemistry of sagittal sections of hippocampus (left panel) and frontal cortex (right panel) from
DYRK1A TG (8-week-old, lower panels) and control littermates (upper panels) performed with pS202 (A) and
pS404 (B) antibodies. Panels a and d, CA1; panels b and e, CA3; panels c and f, polymorphic layer of the dentate
gyrus. A,50; panels a–f,400; B,400. The figures shown are representative of results obtainedwith 3 pairs
of DYRK1A TG and control littermate mice.
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74 6% (n 3, p 0.01) relative to that of control littermates,
respectively (Fig. 6B). Taken together, these results demon-
strate that phosphorylation of Tau at Ser-202 and Ser-404 is
enhancedwhen the amount ofDYRK1A is increased suggesting
that overexpression of DYRK1A is functionally linked to Tau
hyperphosphorylation in vivo.
Interaction of Dyrk1A with Tau—To determine whether
Tau is phosphorylated through the physical interaction with
Dyrk1A, the brain lysates of DYRK1A TG mice were immu-
noprecipitated with anti-Tau-antibody. As shown in Fig. 6C,
immunoprecipitation of Tau led to co-immunoprecipitation
of Dyrk1A, indicating that Dyrk1A interacts with Tau in
DYRK1A TG brains. Furthermore, reverse co-immunopre-
cipitation experiments with anti-Dyrk1A antibody also
revealed an interaction between Dyrk1A and Tau as shown
in Fig. 6C.
DISCUSSION
We show here that Tau residues at Ser-202, Thr-212, and
Ser-404 are phosphorylated by Dyrk1A in vitro and in vivo and
that their phospho-Tau amounts are increased in the brains of
DYRK1A TG mice. This study provides the first in vivo evi-
dence of a physiological role for DYRK1A in Tau hyperphos-
phorylation, a modification that is known to be necessary for
the formation of NFTs in AD. Our transgenic mice show about
50% overexpression of Dyrk1A at the protein level (24) and
70% increase in Dyrk1A kinase activity,4 compared with
those of littermate controls. Despite a slight increase in the
Dyrk1A kinase activity (20%), these TG mice provide a good
clinical model of Down syndrome for studying the roles of
Dyrk1A in vivo. Expression of the DYRK1A protein in the fron-
tal cortex of DS brains was increased by 45% when compared
with age-matched normal controls.4 Therefore, overexpres-
sion of DYRK1A in DS brains, resulting from triplication of
theDYRK1A gene on human chro-
mosome 21, may cause early onset
of AD pathology through the
hyperphosphorylation of Tau
protein.
A recent study showed that
DYRK1A immunoreactivity is also
increased in the frontal cortex,
entorhinal cortex, and hippocam-
pus of ADpatients (30), suggesting a
role for DYRK1A in AD pathogene-
sis. Strong immunohistochemical
signals of phospho-Tau in the neu-
ronal cell bodies of the hippocam-
pus and apical dendrites of the
frontal cortex in DYRK1A TG
mice are consistent with those
from previous studies that showed
that, in AD and other neurodegen-
erative diseases, hyperphosphory-
lated Tau is directed from the
axons to the neural cell bodies and
dendrites (31). The presence of
NFTs in 12-month-old DYRK1A
TG mice brain was not detected using the silver method of
Campbell (43) and Gallyas (44), possibly either because the
mice were not old enough for development of NFTs or
because DYRK1A-mediated Tau hyperphosphorylation
alone is not sufficient for the formation of NFTs (data not
shown). In future studies, it will be interesting to determine
whether the elevations in Tau phosphorylation observed in
DYRK1A TG mice enhance the formation of NFTs, either in
aged DYRK1A mice or when they are crossed with mouse
models that produce tangles.
Phosphorylation of proline-rich regions of Tau induces con-
formational changes (32), which may cause global structural
and functional transformations of Tau from its less-phospho-
rylated, microtubule-bound form to its hyperphosphorylated,
aggregated form. Consistent with this, Tau phosphorylation by
Dyrk1A strongly inhibited the ability of Tau to promotemicro-
tubule assembly (Fig. 3). In the Tau hyperphosphorylation cas-
cade, which culminates in NFT formation, the AT8 epitopes
(pSer-202 and pThr-205) were visible prior to the generation of
NFTs (31). It has been reported that phosphorylation at Ser-202
enhances Tau polymerization and that phosphorylation at both
Ser-202 and Thr-205 not only induces polymerization but also
facilitates filament formation (33). An analysis of pseudo-phos-
phorylation at the Thr-212 residue of Tau indicates that this
phosphorylation event may act primarily to stabilize filaments
by slowing the rates of dissociation (34). The PHF-1 antibody,
which recognizes Tau phosphorylation at Ser-396/Ser-404,
specifically stains AD brain sections (35), and phosphorylation
at Ser-396/Ser-404 has been reported to enhance Tau polym-
erization and to attenuate the ability of Tau to stabilize micro-
tubules (36). Therefore, the present findings, in which Tau is
phosphorylated by Dyrk1A at Ser-202, Thr-212, and Ser-404,
suggest important roles for DYRK1A in the loss of microtubule
assembly and in the formation of NFTs.
FIGURE 6. Immunoblotting analysis of pS202 and pS404 levels in the DYRK1A TG mice. A, immunoblots
(left panel) of hippocampal lysates from 4- to 24-week-old DYRK1A TG mice (TG) and control littermates (con)
carried out with Dyrk1A, pS202, pS404, and Tau antibodies. Densitometric analysis (right panel) of the immu-
noblotswas normalizedwith respect to the Tau signal. The amount of pS202 andpS404 in theDYRK1ATGmice
is plotted as the percent of that in wild-type littermate controls. Data are shown as means S.E. *, p 0.05;
**, p 0.01 versus littermate control by Student’s t test. B, immunoblots of frontal cortex lysates fromDYRK1A
TG mice (TG) and control littermates (con) carried out with Dyrk1A, pS202, pS404, and Tau antibodies.
C, co-immunoprecipitation (IP). Brain lysate (1 mg) from DYRK1A TGmice was immunoprecipitated with con-
trol IgG, anti-Tau, or anti-Dyrk1A antibody (Ab) and thenwas subject to immunoblot analysis for the indicated
antibodies. The position of mouse immunoglobulin is marked IgG. Input, 10 g of brain lysate.
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It has been reported that the reduction of the ability of Tau to
promote microtubule assembly is proportional to the level of
Tau phosphorylation (28). Phosphorylation by Dyrk1A
strongly reduced the ability of Tau to promote microtubule
assembly (Fig. 3). The effect was comparable with that of JNK2,
which potentially phosphorylates 10 Tau residues (27).
Therefore, it is likely that in addition to the three phosphoryl-
ated residues, pS202, pT212, and pS404, examined here, addi-
tional Tau residues could be phosphorylated by Dyrk1A. Given
that all potential phosphorylation sites of Tau in DYRK1A TG
mice were not extensively examined, the link, if any, between
DYRK1A and other Tau phosphorylation sites remains to be
elucidated. In contrast to this study, a recent study concluded
that DYRK1A phosphorylated only the Thr-212 residue in Tau
(28). This discordant finding between that investigation and the
present study is likely because of the preparation of Dyrk1A.
Glutathione S-transferase-tagged truncated Dyrk1A (1–500
amino acids) was used to phosphorylate Tau in a previous study
(28), whereas the full-length Dyrk1A (1–763 amino acids) was
used in this study. Yoshida and Goedert (37) reported that the
phosphorylated Tau by Dyrk1A inhibited microtubule assem-
bly. However, they also used glutathione S-transferase-tagged
truncated Dyrk1A (1–500 amino acids), and the inhibition was
minimal (less than 15%), whereas we used the full-length
Dyrk1A (1–763 amino acids) and the inhibition was much
stronger (80  7%, p  0.01). It is possible that either a gluta-
thione S-transferase tag at the N terminus potentially inhibits
the interaction of Dyrk1A with Tau or that a C-terminal
domain of Dyrk1A is necessary for efficient interaction with
and for the phosphorylation of Tau.
A previous study showed that Tau is phosphorylated by
Dyrk1A in vitro at the Thr-212 residue and that this phospho-
rylation primes Tau for phosphorylation by GSK3 (27). How-
ever, increased Tau phosphorylation at Thr-212was not detected
inDyrk1AcDNA-containing transgenicmice in an immunohisto-
chemical analysis (30).Thediscrepancybetween thedataobtained
withDyrk1AcDNATGmice (30) and theDYRK1ATGmiceused
in this study (24) may have resulted from the difference in the
promoters used for the production of the transgenic mice. The
exogenous inducible sheepmetallothionein-Ia promoterwas used
to drivemouseDyrk1A expression in cDNA transgenicmice (25),
whereas the endogenous human promoter was used to drive
expression of the humanDYRK1A gene in the DYRK1ATGmice
(24). It is also possible that the seven amino acid differences that
exist between the human andmouse Dyrk1A proteins contribute
to this conflicting result.
The following mechanism is proposed for the regulation of
early onset of AD in DS brains. DYRK1A immunoreactivity is
increased in the frontal cortex, entorhinal cortex, andhippocam-
pus of AD patients (30), suggesting a role for DYRK1A in AD
pathogenesis. It was recently found that Dyrk1A also phosphoryl-
atedAPP at Thr-668 in vitro and in vivo, and it caused an increase
in theamountsof-amyloid.4The increasedamountsofDYRK1A
in DS brains give rise to the hyperphosphorylation of Tau (this
study) and elevated amounts of A via an enhanced phosphoryla-
tion of APP.4 These processes possibly contribute to the early
onset of AD pathogenesis in DS brains. Emerging evidence sug-
gests that the plaques and NFTs are indications of disease but are
not the cause of AD, thereby therapeutic approaches aimed at
reducing the levels ofA and abnormalTau phosphorylationmay
be effective (38–42). From the results herein, we propose that
DYRK1A can serve as a potential therapeutic target for the treat-
ment of AD in both DS and AD patients.
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